There was a significantly greater frequency of response among patients treated with CIFX compared to cisplatin alone (31.1% vs 17.8%) .
Progression free survival was also significantly longer for the CIFX group when compared to cisplatin alone .
There was no significant difference in survival between cisplatin and either of the other combination regimens .
Toxicity was significantly worse for the two combination arms when compared to cisplatin alone .
